SAN DIEGO, — Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that the New York Department of Health’s Wadsworth Center Clinical Laboratory Evaluation Program (CLEP) has issued a clinical laboratory permit to allow the Sequenom Center for Molecular Medicine’s (Sequenom CMM) San Diego facility to provide its noninvasive prenatal laboratory-developed test, the MaterniT21™ PLUS test, to healthcare professionals in the state of New York, effective August 1, 2013.

In addition, Sequenom CMM’s CLIA laboratory location in North Carolina has received accreditation by the College of American Pathologists (CAP), indicating that it has met all applicable standards required by the organization to provide quality laboratory services. At this time, Sequenom CMM offers bicoastal laboratory testing services to healthcare professionals, as all three laboratory sites located in California, Michigan and North Carolina are CLIA-certified and CAP-accredited, demonstrating they meet the highest quality and safety standards for laboratory testing.

“The New York licensure and approval process is a very detailed and complex evaluation by a regulatory body to ensure the accuracy and reliability of laboratory testing that is provided throughout New York State, and we believe the successful CLEP permit, in addition to the recent CAP accreditation in North Carolina, further validate the clinical, technical and scientific merits of our industry-leading noninvasive prenatal technology,” said Allan Bombard, M.D., Chief Medical Officer of Sequenom, Inc. “We are proud of the issuance of the New York State Department clinical laboratory permit that will enable healthcare providers to offer critical and timely information to expectant families, and we look forward to working with physicians in New York to better serve their patients.”

The MaterniT21 PLUS test analyzes the relative amount of 21, 18, 13, as well as X and Y chromosomal material in cell-free DNA. The test is intended for use in pregnant women at increased risk for fetal aneuploidy and can be used as early as 10 weeks’ gestation. Estimates suggest there are about 750,000 pregnancies at increased risk for fetal aneuploidy each year in the United States. The MaterniT21 PLUS test is available exclusively through the Sequenom CMM as a testing service provided to physicians. To learn more about the test, please visit www.Sequenomcmm.com.